Your browser doesn't support javascript.
Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine.
Basile, Kerri; Rockett, Rebecca J; McPhie, Kenneth; Fennell, Michael; Johnson-Mackinnon, Jessica; Agius, Jessica E; Fong, Winkie; Rahman, Hossinur; Ko, Danny; Donavan, Linda; Hueston, Linda; Lam, Connie; Arnott, Alicia; Chen, Sharon C-A; Maddocks, Susan; O'Sullivan, Matthew V; Dwyer, Dominic E; Sintchenko, Vitali; Kok, Jen.
  • Basile K; Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  • Rockett RJ; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Sydney, NSW 2145, Australia.
  • McPhie K; Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW 2006, Australia.
  • Fennell M; Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  • Johnson-Mackinnon J; The Westmead Institute for Medical Research, Westmead, Sydney, NSW 2145, Australia.
  • Agius JE; Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  • Fong W; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Sydney, NSW 2145, Australia.
  • Rahman H; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Sydney, NSW 2145, Australia.
  • Ko D; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Sydney, NSW 2145, Australia.
  • Donavan L; Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  • Hueston L; Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  • Lam C; Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  • Arnott A; Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  • Chen SC; Menzies Health Institute Queensland, Griffith University, Brisbane, QLD 4222, Australia.
  • Maddocks S; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Sydney, NSW 2145, Australia.
  • O'Sullivan MV; Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  • Dwyer DE; Centre for Infectious Diseases and Microbiology Laboratory Services, NSW Health Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, Sydney, NSW 2145, Australia.
  • Sintchenko V; Centre for Infectious Diseases and Microbiology-Public Health, Westmead Hospital, Sydney, NSW 2145, Australia.
  • Kok J; Sydney Institute for Infectious Diseases, The University of Sydney, Sydney, NSW 2006, Australia.
Viruses ; 14(9)2022 09 13.
Article in English | MEDLINE | ID: covidwho-2033143
ABSTRACT
In late November 2021, the World Health Organization declared the SARS-CoV-2 lineage B.1.1.529 the fifth variant of concern, Omicron. This variant has acquired over 30 mutations in the spike protein (with 15 in the receptor-binding domain), raising concerns that Omicron could evade naturally acquired and vaccine-derived immunity. We utilized an authentic virus, multicycle neutralisation assay to demonstrate that sera collected one, three, and six months post-two doses of Pfizer-BioNTech BNT162b2 had a limited ability to neutralise SARS-CoV-2. However, four weeks after a third dose, neutralising antibody titres were boosted. Despite this increase, neutralising antibody titres were reduced fourfold for Omicron compared to lineage A.2.2 SARS-CoV-2.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: V14092023

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: V14092023